louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01922960: Microcirculatory Assessment in Patients With Trauma and Severe Burns
Official title: Microcirculatory Assessment in Patients With Trauma and Severe Burns
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Burns
Trauma
Keywords: trauma
multiple organ dysfunction syndrome
Lead sponsor: University of South Alabama
Sponsor class: OTHER
First posted: 2013-08-14
Enrollment: 0
Sex: ALL
Minimum age (years): 19
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Predict the development of multiple organ failure in patients with trauma and severe burns.

Detailed description: Microvascular alterations are frequently seen in patients with sepsis, trauma, burns and those who are hemodynamically uncompensated(Shock).

The use of the Microscan is a non-invasive approach to visualize and assess impaired mucosal microcirculation in order to identify early on patients who are predisposed for MOF (multiple organ failure)

Eligibility criteria: Inclusion Criteria:

* Patients with severe burns/trauma ages 19-80. Patients undergoing elective abdominal or cardiothoracic surgery ages 19-69 years old

Exclusion Criteria:

* Patients undergoing elective surgery \< 19 years old.

Primary outcomes:
measure: dysfunctional capillary density correlates with development of multiple organ failure
timeFrame: approximately 1 year to assess outcome measure
Secondary outcomes:
Other outcomes:
Locations:
city: Mobile
country: United States
facility: University of South Alabama Medical Center
state: Alabama
Study officials:
affiliation: University of South Alabama, Department of Surgery
name: William O Richards, MD
role: STUDY_CHAIR
References:
Clinical trial NCT05689060: Mulligan Straight Leg Raising Versus Post Facilitation Stretch on Hamstring Flexibility in Physiotherapy Students
Official title: Mulligan Straight Leg Raising Versus Post Facilitation Stretch on Hamstring Flexibility in Physiotherapy Students: Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rehabilitation
Keywords: mulligan technique
facilitation stretch technique
hamstring
flexibility
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-01-18
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: There are several research on Mulligan's techniques that have demonstrated their effectiveness in lowering hamstring tightness, and Mulligan is a pain-free therapy that may be used on any patients complaining of low back pain and hamstring tightness. the purpose of this preliminary study was to determine the effect of Mulligan technique versus post facilitation stretch technique on hamstring flexibility in healthy subjects


Eligibility criteria: Inclusion Criteria:

* age 18-25 years
* had 20-50 degrees active knee extension loss with hip and knee in 90 degrees (popliteal angle)

Exclusion Criteria:

* lower limb and spinal deformity,
* hamstring injuries and tightness associated with muscle soreness,
* history of fracture or surgery of back pelvis,

Primary outcomes:
measure: Active knee extension test
timeFrame: after two months
measure: Passive compliance
timeFrame: after two months
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Amira Mahmoud Abd-elmonem
Study officials:
affiliation: Cairo university, faculty of physical therapy
name: Reham H Diab, Phd
role: STUDY_CHAIR
References:
Clinical trial NCT06583460: Systematic Intervention to Improve Sexual Dysfunction
Official title: Systematic Intervention to Improve Sexual Dysfunction in Adjuvant Breast Cancer Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Breast Cancer Female
Localized Cancer
Keywords: Sexual dysfunction
Lead sponsor: Center Eugene Marquis
Sponsor class: OTHER
First posted: 2024-09-04
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Category 2 clinical trial, monocentric, prospective, comparative, controlled but not randomized
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this clinical trial is to compare the benefit of early, systematic, multidisciplinary oncosexological care versus on-demand care on the sexual health of women with breast cancer.

Detailed description: The aim of the study is to evaluate the effectiveness of early, systematized oncosexology care on perceived sexual health at 18 months, compared with oncosexology care on demand.

All included patients are evaluated at Baseline and M18 following initiation of antineoplastic treatments associated with surgery. Patients who accepted additional oncosexological care were also assessed at M4, M8 and M12. The content of support care is detailed in section "arms and interventions".

Oncosexology consultations with the sexologist and the medical support care of any organic disorders remain accessible to all patients, on request, including the group of patients who do not wish to participate in early and systematic oncosexology care.

Eligibility criteria: Inclusion Criteria:

* Women ≥ 18 years (menopausal or not),
* Localized breast cancer with or without lymph node involvement,
* Initial treatment starting with surgical resection, whatever the associated therapy (chemotherapy, radiotherapy, hormone therapy, monoclonal antibody, conjugated drug antibody, targeted therapy such as cyclin and anti-PARP inhibitors, etc.),
* Patient affiliated or benefiting from the social security system,
* Patient informed and informed consent signed.

Exclusion Criteria:

* History of cancer (except squamous cell carcinoma or basal cell carcinoma) in the last five years,
* Pregnant or breast-feeding women,
* Patients deprived of their liberty, under guardianship or curatorship and all other administrative safeguards,
* Patients unable to comply with the study schedule for social, medical or psychological reasons.

Primary outcomes:
measure: Sexual satisfaction
timeFrame: Measured at baseline and at 18 months following initiation of treatment and surgical.
Secondary outcomes:
Other outcomes:
Locations:
city: Rennes
country: France
facility: Centre de Lutte contre le Cancer Eugène Marquis
state: Bretagne
Study officials:
affiliation: Centre de Lutte Contre Le cancer Eugène Marquis
name: Claudia Lefeuvre-Plesse, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04305860: Acceptance of Different Thickeners in Dysphagia
Official title: Acceptance of Different Types of Thickeners, With and Without Flavoring, in Patients With Dysphagia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dysphagia
Dysphagia, Oropharyngeal
Keywords: Thickener
Flavoring
Dysphagia
Lead sponsor: Complexo Hospitalario Universitario de A Coruña
Sponsor class: OTHER
First posted: 2020-03-12
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Pilot study of nutritional intervention, randomized, and controlled
Primary purpose: TREATMENT

Brief summary: Randomized, controlled, pilot study of nutritional intervention to evaluate the acceptance to different kinds of thickeners, with and without the addition of flavoring.

Detailed description: Background:

In patients with dyaphagia the modification of viscosity of oral liquids with thickeners ia needed to guarantee an effective and safe swallowing, and to ensure a proper state of hydration. There are two types of thickeners: thickeners obtained from modified starch or from food gums (suchxanthan gum)

Aim:

To evaluate the acceptance of different types of thickeners, with and without the addition of flavorings, and their relationship with water intake.

Methods:

Randomized, controlled, pilot study of nutritional intervention. Forty hospitalized patients with oropharyngeal dysphagia were randomized to 4 parallel groups: modified starch without flavoring, modified starch with flavoring, xanthan gum without flavoring, xanthan gum with flavoring. Each patient was asked to assess the odor, taste, appearance, and overall valoration of the thickened liquid with the different preparations, using a structured questionnaire. The number of glasses consumed by the patient over 3 consecutive days was also recorded to calculate de volume of liquid they consumed.

Eligibility criteria: Inclusion Criteria:

* Patients with oropharyngeal dysphagia for liquids diagnosed before admission or during hospitalization and who need thickener.

Exclusion Criteria:

* Patients with expected hospital length of stay less than 24 hours.
* Patients with food allergy to any of the ingredients of the thickener or flavorings used in the study.
* Patients with cognitive impairment that prevents collaborating in obtaining data.
* Patients in terminal situations, in which death is expected in the following hours.

Primary outcomes:
measure: Hydratation
timeFrame: 3 days during hospitalization
measure: Taste
timeFrame: 3 days during hospitalization
measure: Odor
timeFrame: 3 days during hospitalization
measure: Appearance
timeFrame: 3 days during hospitalization
measure: Overall valoration
timeFrame: 3 days during hospitalization
Secondary outcomes:
Other outcomes:
Locations:
city: A Coruña
country: Spain
facility: Alfonso Vidal-Casariego
state: La Coruna
Study officials:
References:
Clinical trial NCT00793260: Deep Dive Randomized Control Trial
Official title: Deep Dive Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Disease
Arthritis
Uterine Diseases
Spinal Diseases
Preventive Health Services
Lead sponsor: Health Dialog
Sponsor class: INDUSTRY
Collaborators: name: Health Net California
name: Highmark Blue Cross Blue Shield
First posted: 2008-11-19
Enrollment: 174120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Compare two care management support program models on medical costs and utilization.


Eligibility criteria: Inclusion Criteria:

* All employees, dependents and retirees in one of seven large employer groups, including a state university system, a state employee group, two manufacturing companies, a natural resource extraction company, a public educational service agency, and a nonprofit multiple employer association for independent colleges were eligible for inclusion.

Exclusion Criteria:

* no financial information was available from their facility and professional claims;
* they were in an employer sub-group ineligible for care support services;
* they asked not be to contacted or were deceased;
* gender information was missing from their eligibility files;
* their claims data from the year prior to the start of the study indicated diagnoses of HIV, AIDS, end-stage renal disease (ESRD), organ transplants, or necrotizing fasciitis (intended to improve the likelihood of a balanced distribution of costs and conditions); OR
* they were in an employer sub-group with less than four months of enrollment prior to the study start date (resulting in too little information for stratification).

Primary outcomes:
measure: The primary outcome measure was total medical costs (capped at $200,000 per individual per year) and pharmacy costs.
Secondary outcomes:
measure: Secondary measures included utilization of selected services.
Other outcomes:
Locations:
city: Portland
country: United States
facility: Health Dialog Analytic Solutions, Inc
state: Maine
Study officials:
affiliation: Health Dialog
name: David E Wennberg, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wennberg DE, Marr A, Lang L, O'Malley S, Bennett G. A randomized trial of a telephone care-management strategy. N Engl J Med. 2010 Sep 23;363(13):1245-55. doi: 10.1056/NEJMsa0902321.
Clinical trial NCT00006160: African-American Diabetes Intervention Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insulin-Dependent Diabetes Mellitus
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor class: NIH
First posted: 2000-08-09
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: A controlled trial to assess the potential benefit of a home based worker in improving control in African-American children with insulin dependent diabetes.


Eligibility criteria: Inclusion Criteria:

* Insulin dependent diabetes mellitus

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Case Western Reserve University
state: Ohio
Study officials:
References:
Clinical trial NCT00184860: The Role of CT-PET-MRI Image Fusion in Determining Radiation Treatment Volumes of Head-and-Neck Cancer Patients
Official title: The Value of CT-PET-MRI Image Fusion in Determining Radiation Treatment Volumes in Patients With a Squamous Cell Carcinoma of the Head-and-Neck Region, Who Are to be Treated With Definitive Radiotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Head and Neck Neoplasms
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Technical developments in radiation oncology are making it possible to deliver a prescribed radiation dose to radiation target volume with increasing accuracy.

Therefore it is becoming even more relevant to accurately define the radiation target volumes.

The current standard in defining radiation target volumes in patients with head-and-neck cancer is to combine physical examination data with a CT-scan in the treatment position.

The goal of this investigation is to analyse the rol of CT-PET-MRI image fusion in defining radiation target volumes.


Eligibility criteria: Inclusion Criteria:

Patients eligible for definitive radiotherapy with a Head and Neck Neoplasm (squamous cell carcinoma) in one of the following anatomical sites:

* oral cavity
* oropharynx
* hypopharynx
* larynx

Exclusion Criteria:

* age \< 18 years
* pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Nijmegen
country: Netherlands
facility: Radboud University Nijmegen Medical Centre
state: Gelderland
Study officials:
affiliation: Radiation oncologist, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
name: Johannes H Kaanders, MD. PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00490360: Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
Official title: Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Cancer of the Pancreatic Head
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2007-06-22
Enrollment: 2007
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.

Detailed description: Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After restaging excludes disease progression, a standard Whipple procedure is performed.

Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30.

* Trial with medicinal product

Eligibility criteria: Inclusion criteria: - Age \> 18 years

* Histologically or cytologically confirmed resectable ductal adenocarcinoma of the pancreatic head
* WHO-performance status 0-2
* Written informed consent
* Discussion in an intrdisciplinary conference

Exclusion criteria: - Insufficient renal function (calculated creatinin clearance \< 60ml(min)

* Insufficient hematologic function (neutrophil count \<1'000/ul, platelets \< 100'000/ul)
* Uncorrectable coagulopathy
* Severe cholestasis (bilirubin \>100mmol/l)
* Distant metastases in liver, lungs or other organs
* Peritoneal carcinomatosis
* Unresectable tumor (s. 4.2.)
* Contraindication for Whipple procedure
* Uncontrolled infection
* Neurotphil count \> Â°2
* Estimated life experience \< 6 months
* HIV Infection
* Severe medical or psychatric comorbidities which interefere with the participation in this trial or the informed consent
* Female patients in child-bearing age without adequate contraception

Primary outcomes:
measure: Resectability rate > 70% after restaging
timeFrame: 2007
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital of Zurich, Department of Surgery
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: 01 Studienregister MasterAdmins
role: STUDY_DIRECTOR
References:
citation: Heinrich S, Schafer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, Clavien PA. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008 Dec;248(6):1014-22. doi: 10.1097/SLA.0b013e318190a6da.
Clinical trial NCT00656760: PET/CT: Role in Detecting Unknown Primary Head and Neck Cancer
Official title: The Clinical Utility of PET-CT in the Management of Squamous Cell Carcinoma of Neck Nodes With an Unknown Primary Malignancy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Head and Neck Cancer
Keywords: unknown primary, head and neck cancer, squamous cell carcinoma
Unknown primary head and neck cancer
Lead sponsor: University of Calgary
Sponsor class: OTHER
Collaborators: name: Tom Baker Cancer Centre
First posted: 2008-04-11
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Historically metastatic squamous cell carcinoma in a cervical lymph node from an occult primary malignancy of the head and neck was evaluated with panendoscopy and biopsies of high risk areas, such as the base of tongue, nasopharynx, and tonsils. This diagnostic protocol identifies the primary malignancy in about 50% of cases. In recent years, the availability of CT has slightly increased the detection rate to 65% when used as an adjunct to the traditional work-up. Studies using PET as an adjunct are conflicting with detection rates ranging up to 75%. Currently, no prospective study has analyzed the role of the PET-CT fusion in the work-up of an occult primary malignancy of the head and neck. This study will compare the detection rate of the traditional work-up to a new protocol involving a pre-operative diagnostic PET-CT.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years old
* Biopsy proven SCC in a cervical lymph node
* Unknown primary cancer after: History, Physical exam, and office endoscopy by otolaryngologist
* Negative Chest X-Ray for malignancy
* Patient consent signed to undergo investigative protocol

Exclusion Criteria:

* Un-fit for general anesthesia
* Unable to lie flat for 45 minutes
* Unable to fast for \> 6 hours
* Unable to perform PET-CT (Obesity \> 150kg)
* Pregnant
* Prior Head and Neck cancer
* Any invasive cancer (Non-Head and Neck) within the last 2 years

Primary outcomes:
measure: proportion of patients where PET/CT resulted in a change in diagnosis
timeFrame: 2 weeks after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
Study officials:
References:
Clinical trial NCT02751060: Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease
Official title: Evaluation of Plasma Non-coding RNAs (miRNA-320a) as Biomarkers of Diagnosis, Prognosis and Treatment Effects in Coronary Heart Disease
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Coronary Disease
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2016-04-26
Enrollment: 4000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 4000 outpatients or hospitalized patients with coronary heart diseasewill be enrolled in this study.

Brief summary: The purpose of this study is to determine whether the expression level of miR-320a are effective as biomarker in evaluating the diagnosis, prognosis and treatment effects of coronary heart disease.


Eligibility criteria: Inclusion Criteria:

1. 18 years of age or older;
2. the most recent symptoms of coronary heart disease within 7 days;
3. meet one of the following conditions: A. clinical history of typical ischemic chest pain (more than 5 minutes of persistent chest pain); B. serum cardiac biomarkers positive (TnT/I or creatine kinase peak greater than 99% of URL); C. Electrocardiogram changes of myocardial ischemia.

Exclusion Criteria:

1. pregnant women or plan to;
2. participate in any drug clinical trials within 3 months;
3. patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years;
4. serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients);
5. previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix);
6. patients refused to comply with the requirements of this study to complete the research work;
7. according to the researchers, patients can not complete the study or not to comply with the requirements of this study (because of the reasons for the management or other reasons).

Primary outcomes:
measure: the plasma expression of miR-320a in coronary heart disease patients compared to control patients
timeFrame: up to 24 months
Secondary outcomes:
measure: number of participants with cardiovascular causes of death
timeFrame: up to 24 months
measure: number of participants with non fatal myocardial infarction or stroke
timeFrame: up to 24 months
measure: number of participants with re-hospitalization due to cardiovascular causes
timeFrame: up to 24 months
measure: number of participants with all causes of mortality
timeFrame: up to 24 months
measure: number of participants with myocardial infarction re-exacerbation or re-hospitalization
timeFrame: up to 24 months
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital
state: Hubei
Study officials:
affiliation: Tongji Hospital
name: Dao Wen Wang, Doctor
role: PRINCIPAL_INVESTIGATOR
References: